Stemmatters SA
Stemmatters SA is a Portuguese cGMP-certified CDMO specializing in regenerative medicine, offering contract development, manufacturing, analytical, and formulation services for cell therapies, ATMPs, and biomaterial-based combination products to biotech and academic clients.
- Company typePrivate
- Founded2007
- HeadquartersGuimarães, Portugal
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Stemmatters SA does
Stemmatters SA is a privately held Portuguese biotechnology company founded in 2007 and headquartered at the Avepark Science and Technology Park in Guimarães, Portugal. It operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) focused on regenerative medicine, including cell therapies, advanced therapy medicinal products (ATMPs), blood-derived biologicals, and combination products built on its biomaterial platform. Its offering spans four service pillars: contract development, cGMP contract manufacturing, analytical services, and formulation development, supplemented by proprietary programs such as the TheraBoost biomaterial platform and the RHYTHMS iPSC process-control toolkit.
The company serves regenerative medicine developers, academic medical centers, and cell therapy companies through enterprise B2B engagements, with named partners including Pluristyx, Accelerated Biosciences, IPO Porto, and NOVA FCT. It holds GMP certification and EudraGMDP registration, is ISO 9001:2015 certified, and has integrated advanced instrumentation including the Agilent xCELLigence real-time cell analysis system and the Limula LimONE automated manufacturing platform. Stemmatters is also a leader or partner in multiple EU and Portuguese funded consortia (CAR T-REX, PAT4CGT, DCMatters, CAR T-Matters, RHYTHMS), which collectively have brought in over €11 million in non-dilutive funding between 2022 and 2025 and underpin its technology and capability build-out.
Commercially, Stemmatters generates revenue through project-based CDMO service contracts (development, manufacturing, analytical, and formulation work) with quote-based pricing that is not publicly disclosed. The company supplements commercial service revenue with substantial non-dilutive grant income, and pursues a horizontal segmentation strategy targeting regenerative medicine companies, academic medical centers, and cell therapy developers. Its go-to-market is primarily enterprise field sales supplemented by conference-driven lead generation at ISCT, BIO-EUROPE, and Advanced Therapies events, with thought leadership reinforced through scientific publications and consortium leadership.
Stemmatters SA firmographics
Firmographics- Name
- Stemmatters SA
- Legal name
- Stemmatters, Biotecnologia e Medicina Regenerativa S.A.
- Website
- https://stemmatters.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Stemmatters SA is a Portuguese cGMP-certified CDMO specializing in regenerative medicine, offering contract development, manufacturing, analytical, and formulation services for cell therapies, ATMPs, and biomaterial-based combination products to biotech and academic clients.
- Ownership category
- akta.pro rank
Stemmatters SA industry classification
Industry- Product category
- Biopharmaceutical CDMO Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy CDMO (HLAGABAD)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
Keywords
Where Stemmatters SA is headquartered
LocationHeadquarters
- HQ city
- Guimarães
- HQ country
- Portugal
- HQ region
- Europe
Offices1 record
Markets served
Stemmatters SA business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Contract Development Services: Process development and optimisation services for advanced therapy products, supporting clients from early development through clinical translation
- cGMP Manufacturing: Manufacturing services for cell therapies, ATMPs, and biological products under current Good Manufacturing Practices
- Analytical Services: Quality control testing and analytical method development for characterization of cell-based products
- Formulation Development:
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Stemmatters SA product offering
Product offeringCore offering
Stemmatters SA operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine products, including cell therapies, advanced therapy medicinal products (ATMPs), and blood-derived biologicals. The company delivers end-to-end process development, cGMP contract manufacturing, analytical testing, and formulation development services to biotechnology and pharmaceutical clients. Operations span from material reception through fill-and-finish, batch release, storage, and retrieval under GMP-certified conditions.
Product overview
Stemmatters SA operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine products. Its core offering consists of four interconnected service pillars: Contract Development (process development and CMC support for cGMP translation), Contract Manufacturing (end-to-end cGMP production from material reception through fill-and-finish and batch release), Analytical Services (quality, safety, and regulatory compliance testing), and Formulation Development (biomaterial-enabled combination product development). These services are complemented by the Stemmatters Academy internal training program. The company also advances proprietary technology programs including TheraBoost (an engineered biomaterial platform for cell and gene therapy supply chain innovation) and the RHYTHMS project (advanced process control toolkit for iPSC manufacturing monitoring), targeting the advanced therapy community including human cell and tissue products, advanced cell therapies, and blood-derived biologicals.
Differentiator
Problem solved
Functional benefit
Brands
- TheraBoost: An engineered biomaterial platform developed to address critical challenges in the supply chain of cell and gene therapies (CGTs). The platform aims to improve manufacturing, transport, and scalability of advanced therapies through three innovations: Cell Engineering Platform, Cell Expansion Microcarriers, and Hypothermic Shipping Matrix.
Products and services
- Contract Development Services
- Contract Manufacturing Services
- Analytical Services
- Formulation Development Services
Quantifiable outcome
- Successfully treated 100+ patients with CAR T cell therapies through consortium partner IPO Porto
- +2 more outcomes
Companies that use Stemmatters SA
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Stemmatters SA technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Stemmatters SA partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- RHYTHMS ConsortiumminorEurostars-funded project with consortium partners Scinus, MyCellHub, and University Hospital Skåne. Project aims to develop advanced process control toolkit for real-time monitoring of iPSC expansion, enabling data-driven process control and scalable manufacturing protocols.
- LimulacoreInstallation of LimONE device at Stemmatters facility - an all-in-one automated cell and gene therapy manufacturing platform. Partnership spanning over three years with Stemmatters contributing design inputs. Technology transfer part of PAT4CGT project for automated, non-invasive process monitoring.
- CAR T-Matters ConsortiumcorePortuguese consortium led by Stemmatters in partnership with IPO Porto and NOVA FCT. Project aims to establish national capacity for CAR T cell therapy development and production in Portugal. Co-funded by COMPETE 2030 Programme. Stemmatters responsible for implementing CAR T manufacturing process with regulatory compliance.
- Accelerated BiosciencescoreStrategic partnership to co-develop and co-market human iPSCs derived from human trophoblast stem cells (hTSC). Marks Accelerated Biosciences' entry into EU market. Partnership aims to establish capabilities to develop and manufacture hTSC-derived iPSC compliant with EU regulatory requirements.
- CAR T-REX ConsortiumcoreCAR T-REX International Consortium led by Stemmatters awarded €2.7M EIC Pathfinder Open Grant. Consortium includes TargetGene Biotechnologies (Israel), CiQUS (Spain), University of Debrecen (Hungary), and Leibniz-Institut für Immuntherapie (Germany). Project focuses on developing novel CAR T cells to prevent exhaustion in solid tumour treatment.
- PluristyxcorePartnership to develop and manufacture iPSC-derived Mesenchymal Stem Cell (iMSC) banks. Stemmatters provides cGMP manufacturing capabilities while Pluristyx contributes iPSC technology and expertise. Collaboration enables large-scale, custom-designed iMSC production for non-clinical and clinical research projects.
- DCMatters Consortiumminor€2.1M project combining dendritic cell vaccines with immune checkpoint inhibitors for solid tumour treatment. Consortium includes Stemmatters, IPO Porto, NOVA FCT, and CINTESIS. Stemmatters develops and manufactures third-generation dendritic cells with enhanced anti-tumour response capability.
- PAT4CGT ConsortiumcorePAT4CGT consortium awarded €4.7M EIC Pathfinder Grant for developing modular cell and gene therapy manufacturing platform. Consortium coordinated by Da Vinci Labs (France) with technical leader Limula (Switzerland), includes Jobst Technologies, TU Wien, Exothera, and Crowdhelix. Stemmatters provides end-user assessment and closed process validation.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Stemmatters SA competitors and assessment
Company assessmentBroad incumbents
- Lonza Cell & Gene Technologies: Lonza is the largest global CDMO with a dedicated Cell & Gene Technologies business offering process development, viral vector and cell therapy manufacturing. Comparable to Stemmatters as a cGMP cell therapy CDMO serving therapeutic developers, but at vastly greater scale, with multi-site global capacity and broader service offerings.
- Catalent (Novo Holdings): Catalent (now owned by Novo Holdings) is a major global CDMO with significant cell therapy capabilities, including autologous and allogeneic manufacturing and iPSC-related services. It competes with Stemmatters for clinical and commercial cell therapy manufacturing contracts but operates globally at a much larger scale.
- Charles River Laboratories: Charles River offers Cell & Gene Therapy CDMO services through its Manufacturing Solutions segment, including process development and cGMP manufacturing. Comparable to Stemmatters as a cell therapy manufacturing services provider, but operates at much larger scale with a broader preclinical-to-clinical portfolio.
Direct peers
- AGC Biologics: AGC Biologics is a global CDMO offering cell and gene therapy development and manufacturing, including iPSC and cell therapy capabilities. Directly comparable to Stemmatters as a cGMP cell therapy CDMO with similar service pillars (process development, manufacturing, analytical), but with broader geographic footprint and larger capacity.
- RoslinCT: RoslinCT is a Scotland-based CDMO focused on cell and gene therapy manufacturing, including iPSC-derived therapies and allogeneic cell banking. Directly comparable to Stemmatters as a specialist cell therapy CDMO serving regenerative medicine developers with cGMP manufacturing and process development capabilities.
- KBI Biopharma: KBI Biopharma is a CDMO offering cell line development, process development, and cGMP manufacturing for biologics and cell therapies. Comparable to Stemmatters as a specialized CDMO providing development and manufacturing services for advanced therapy developers, though KBI has broader biologics capabilities and a larger footprint.
Regional players
- Cell and Gene Therapy Catapult: Cell and Gene Therapy Catapult operates a UK-based manufacturing center for cell and gene therapy developers, providing process development, manufacturing, and analytical services. Comparable to Stemmatters as a specialized cell therapy manufacturing hub with similar service offerings, primarily serving European developers.
- Exothera: Exothera is a Belgium-based CDMO specializing in viral vectors and cell and gene therapy manufacturing, a PAT4CGT consortium partner of Stemmatters. Comparable as a European specialist CDMO in the cell and gene therapy space with similar scientific orientation and customer profile, though focused more on viral vector production.
Emerging players
- Center for Breakthrough Medicines: Center for Breakthrough Medicines is a US-based cell, gene, and biological therapy CDMO offering process development, manufacturing, and analytical services. Comparable to Stemmatters as a specialized advanced therapy CDMO with end-to-end capabilities, but operating in the US market and at a different stage of growth.
- Limula: Limula is a Swiss-based technology company developing automated cell and gene therapy manufacturing platforms (LimONE device) and a direct PAT4CGT consortium partner of Stemmatters. Adjacent rather than direct competitor — Limula provides automation technology that Stemmatters integrates into its CDMO services, making it a partner and potential ecosystem peer in the European CGT manufacturing value chain.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Stemmatters SA social profiles
Digital presenceStemmatters SA financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stemmatters SA leadership team
Management profileNumber of profiles
Profiles3 records
Stemmatters SA funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stemmatters SA M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stemmatters SA
What does Stemmatters SA do?
Stemmatters SA operates as a fully integrated Contract Development and Manufacturing Organization (CDMO) specializing in regenerative medicine products, including cell therapies, advanced therapy medicinal products (ATMPs), and blood-derived biologicals. The company delivers end-to-end process development, cGMP contract manufacturing, analytical testing, and formulation development services to biotechnology and pharmaceutical clients. Operations span from material reception through fill-and-finish, batch release, storage, and retrieval under GMP-certified conditions.
Is Stemmatters SA a public or private company?
Stemmatters SA is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Stemmatters SA founded?
Stemmatters SA was founded in 2007. It employs 11 to 50 people.
Where is Stemmatters SA based?
Stemmatters SA is headquartered in Guimarães, Portugal, in the Europe region.
How does Stemmatters SA make money?
Four revenue lines are on record. Contract Development Services are the primary driver. The others are cGMP Manufacturing, analytical Services and formulation Development.
Who are Stemmatters SA's main competitors?
Broad incumbents on record are Lonza Cell & Gene Technologies, Catalent (Novo Holdings) and Charles River Laboratories. Direct peers are AGC Biologics, RoslinCT and KBI Biopharma. Regional players are Cell and Gene Therapy Catapult and Exothera. Emerging players are Center for Breakthrough Medicines and Limula.
Does Stemmatters SA have an API?
No public API is recorded for Stemmatters SA.
What industry is Stemmatters SA in?
Stemmatters SA's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAD, Cell Therapy CDMO, with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 5417 and its SIC code is 8731.